Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Com Stk Usd0.01 [Di/Reg S] (MXCN.LN)

Com Stk Usd0.01 [Di/Reg S] (MXCN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

MXCN.LN : 680.000 (unch)
MXCT.LN : 267.000 (-1.29%)
MXCT : 3.23 (-5.56%)
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

MXCN.LN : 680.000 (unch)
MXCT.LN : 267.000 (-1.29%)
MXCT : 3.23 (-5.56%)
MaxCyte to Participate in Two Upcoming Investor Conferences

MXCN.LN : 680.000 (unch)
MXCT.LN : 267.000 (-1.29%)
MXCT : 3.23 (-5.56%)
MaxCyte Appoints Cynthia Collins to its Board of Directors

PSTX : 2.67 (-3.26%)
MXCN.LN : 680.000 (unch)
DMTKQ : 0.0001 (unch)
MXCT.LN : 267.000 (-1.29%)
MXCT : 3.23 (-5.56%)
CERT : 9.99 (+0.30%)
MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024

MXCN.LN : 680.000 (unch)
MXCT.LN : 267.000 (-1.29%)
MXCT : 3.23 (-5.56%)
MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

MXCN.LN : 680.000 (unch)
MXCT.LN : 267.000 (-1.29%)
MXCT : 3.23 (-5.56%)
MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results

45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022 Raises 2022 Core Revenue Growth Guidance to Approximately 30% ROCKVILLE, Md.,...

MXCT : 3.23 (-5.56%)
MXCN.LN : 680.000 (unch)
MXCT.LN : 267.000 (-1.29%)
MaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022

GAITHERSBURG, Md., July 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on...

MXCT : 3.23 (-5.56%)
MXCN.LN : 680.000 (unch)
MXCT.LN : 267.000 (-1.29%)
MaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GAITHERSBURG, Md., May 13, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on...

MXCT : 3.23 (-5.56%)
MXCN.LN : 680.000 (unch)
MXCT.LN : 267.000 (-1.29%)
MaxCyte Reports First Quarter Financial Results

MaxCyte Increases 2022 Core Revenue Growth Guidance to be at least 25% and Reiterates Milestone Revenue Guidance of $4 million...

MXCT : 3.23 (-5.56%)
MXCN.LN : 680.000 (unch)
MXCT.LN : 267.000 (-1.29%)

Barchart Exclusives

Is It Time to Buy This Dividend Stock With Nuclear Energy Upside?
Apart from its prowess in nuclear energy, this energy company is also deploying AI. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar